Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Elevara Medicines Raises $70M Series A to Advance RA and Inflammatory Disease Program
Series AVenture Capital

Elevara Medicines Raises $70M Series A to Advance RA and Inflammatory Disease Program

•October 23, 2025
•Oct 23, 2025
0

Participants

Elevara Medicines

Elevara Medicines

company

Monograph

Monograph

investor

Forbion

Forbion

investor

Sofinnova Partners

Sofinnova Partners

investor

Deal Summary

Elevara Medicines, a London-based clinical-stage biotech focused on rheumatoid arthritis and chronic inflammatory diseases, closed a $70M Series A financing co-led by Forbion and Sofinnova Partners with participation from Monograph Capital. The company will use the proceeds to fund its upcoming Phase 2 clinical trial.

0

Comments

Want to join the conversation?

Loading comments...